CALABASAS, CA AND ABU DHABI, UAE / ACCESS Newswire / August 11, 2025 / NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). This milestone marks the fulfillment of all contingencies required to finalize the previously announced $50 million cornerstone investment from Quazar Investment into NuroMENA Holdings Ltd.
CALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, today announced the award of two competitive NIH STTR (Small Business Technology Transfer) grants totaling $2.5 million. These non-dilutive funds will further advance development of the company’s proprietary therapeutic compound NEO212, which is currently completing its Phase 1 clinical trial.
CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance’s Trader Talk with Kenny Polcari in a podcast episode titled “AI and Biotech Take on Brain Cancer.”
NEW YORK CITY, NEW YORK / ACCESS Newswire / July 30, 2025 / New to The Street, the nation's premier financial media platform for emerging public companies, proudly announces a major media partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI). Under this agreement, NeOnc will be featured in a 12-part national broadcast series, with exclusive monthly interviews airing on Bloomberg Television and Fox Business Network. The series will also include earned media distribution, commercial rotation across national networks, and outdoor billboard campaigns in the most visible financial corridors in the U.S.
CALABASAS, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi Phase 2 clinical-stage biotechnology company pioneering innovative treatments for brain cancers, is proud to announce the signing of a definitive, binding Letter of Intent (LOI) to acquire all outstanding equity interests in a to-be-formed Delaware entity jointly owned by Dr. Ishwar K. Puri and Beth R. Levinson. The IP portfolio, which includes U.S. Patent No. 11,788,057 B2, secured through a Patent Transfer Agreement with McMaster University, features cutting-edge 3D bioprinting, artificial intelligence, and quantum modeling technologies designed to accelerate preclinical drug discovery and high-throughput screening of brain-targeted therapies. These assets will be integrated into NeOnc’s expanding IP platform and will be also part of NeOnc’s Middle East partnership with Quazar Investment Group, which is designed to help drive global innovation and clinical trial execution across the GCC region.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
CALABASAS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced that management will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025.
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- In a press release issued earlier today by NeOnc Technologies Holdings, Inc. under the headline, "NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET," please note "today" in the headline and first paragraph should be "July 24, 2025." The corrected release follows:
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prominent financial commentator Kenny Polcari on YouTube.com/@Floorstocks. The interview will air live today at 11:00 a.m. ET.
CALABASAS, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: execution and transfer of a Sub-License Agreement from NeOnc to its Abu Dhabi onshore operating subsidiary, NuroCure. The Sub-License covers the UAE and the wider GCC and MENA region with respect to NEO100 and NEO212, pursuant to NeOnc’s license from USC Stevens Center for Innovation.
CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: formal approval from NeOnc’s Board of Directors.
CALABASSAS, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, has joined the Russell Microcap® Index following the conclusion of the 2025 Russell indexes annual reconstitution.
CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has signed a non-binding term sheet with Quazar Investment to form a new UAE-based investment and clinical platform focused on the Middle East and North Africa (MENA) region.
